198 related articles for article (PubMed ID: 18949060)
1. A role for microRNA in cystic liver and kidney diseases.
Chu AS; Friedman JR
J Clin Invest; 2008 Nov; 118(11):3585-7. PubMed ID: 18949060
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease.
Lee SO; Masyuk T; Splinter P; Banales JM; Masyuk A; Stroope A; Larusso N
J Clin Invest; 2008 Nov; 118(11):3714-24. PubMed ID: 18949056
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.
Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Masyuk AI; Gradilone SA; Gajdos GB; Chandok N; Bakeberg JL; Ward CJ; Ritman EL; Kiyokawa H; LaRusso NF
Gastroenterology; 2012 Mar; 142(3):622-633.e4. PubMed ID: 22155366
[TBL] [Abstract][Full Text] [Related]
4. Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease.
Wang X; Harris PC; Somlo S; Batlle D; Torres VE
Nephrol Dial Transplant; 2009 Feb; 24(2):526-34. PubMed ID: 18826972
[TBL] [Abstract][Full Text] [Related]
5. Aberrant expression of laminin-332 promotes cell proliferation and cyst growth in ARPKD.
Vijayakumar S; Dang S; Marinkovich MP; Lazarova Z; Yoder B; Torres VE; Wallace DP
Am J Physiol Renal Physiol; 2014 Mar; 306(6):F640-54. PubMed ID: 24370592
[TBL] [Abstract][Full Text] [Related]
6. New insights into the molecular pathophysiology of polycystic kidney disease.
Murcia NS; Sweeney WE; Avner ED
Kidney Int; 1999 Apr; 55(4):1187-97. PubMed ID: 10200981
[TBL] [Abstract][Full Text] [Related]
7. B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.
Holditch SJ; Schreiber CA; Harris PC; LaRusso NF; Ramirez-Alvarado M; Cataliotti A; Torres VE; Ikeda Y
Kidney Int; 2017 Sep; 92(3):657-668. PubMed ID: 28416225
[TBL] [Abstract][Full Text] [Related]
8. The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease.
Lager DJ; Qian Q; Bengal RJ; Ishibashi M; Torres VE
Kidney Int; 2001 Jan; 59(1):126-36. PubMed ID: 11135065
[TBL] [Abstract][Full Text] [Related]
9. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.
Masyuk TV; Masyuk AI; Torres VE; Harris PC; Larusso NF
Gastroenterology; 2007 Mar; 132(3):1104-16. PubMed ID: 17383431
[TBL] [Abstract][Full Text] [Related]
10. ARPKD and ADPKD: first cousins or more distant relatives?
Kaimori JY; Germino GG
J Am Soc Nephrol; 2008 Mar; 19(3):416-8. PubMed ID: 18272839
[No Abstract] [Full Text] [Related]
11. Role of follicle-stimulating hormone on biliary cyst growth in autosomal dominant polycystic kidney disease.
Onori P; Mancinelli R; Franchitto A; Carpino G; Renzi A; Brozzetti S; Venter J; Francis H; Glaser S; Jefferson DM; Alpini G; Gaudio E
Liver Int; 2013 Jul; 33(6):914-25. PubMed ID: 23617956
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the understanding of polycystic kidney disease.
Bacallao RL; Carone FA
Curr Opin Nephrol Hypertens; 1997 Jul; 6(4):377-83. PubMed ID: 9263688
[TBL] [Abstract][Full Text] [Related]
13. Macrophages promote polycystic kidney disease progression.
Swenson-Fields KI; Vivian CJ; Salah SM; Peda JD; Davis BM; van Rooijen N; Wallace DP; Fields TA
Kidney Int; 2013 May; 83(5):855-64. PubMed ID: 23423256
[TBL] [Abstract][Full Text] [Related]
14. Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease.
Banales JM; Masyuk TV; Bogert PS; Huang BQ; Gradilone SA; Lee SO; Stroope AJ; Masyuk AI; Medina JF; LaRusso NF
Am J Pathol; 2008 Dec; 173(6):1637-46. PubMed ID: 18988797
[TBL] [Abstract][Full Text] [Related]
15. Epithelial transport in polycystic kidney disease.
Sullivan LP; Wallace DP; Grantham JJ
Physiol Rev; 1998 Oct; 78(4):1165-91. PubMed ID: 9790573
[TBL] [Abstract][Full Text] [Related]
16. Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease.
Masyuk T; Masyuk A; Trussoni C; Howard B; Ding J; Huang B; LaRusso N
JHEP Rep; 2021 Oct; 3(5):100345. PubMed ID: 34568801
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Changes in Polycystic Kidney Disease as a Potential Target for Systemic Treatment.
Haumann S; Müller RU; Liebau MC
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32847032
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in understanding ion transport mechanisms in polycystic kidney disease.
Sudarikova AV; Vasileva VY; Sultanova RF; Ilatovskaya DV
Clin Sci (Lond); 2021 Nov; 135(21):2521-2540. PubMed ID: 34751394
[TBL] [Abstract][Full Text] [Related]
19. Distribution of alpha-integrin subunits in fetal polycystic kidney diseases.
Daïkha-Dahmane F; Narcy F; Dommergues M; Lacoste M; Beziau A; Gubler MC
Pediatr Nephrol; 1997 Jun; 11(3):267-73. PubMed ID: 9203171
[TBL] [Abstract][Full Text] [Related]
20. Molecular and cellular pathophysiology of autosomal recessive polycystic kidney disease (ARPKD).
Sweeney WE; Avner ED
Cell Tissue Res; 2006 Dec; 326(3):671-85. PubMed ID: 16767405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
